CCM NYSE Services-Offices & Clinics Of Doctors Of Medicine Financials FY2016βFY2025
Concord Medical Services Holdings Ltd had $64.1M of revenue in fiscal 2025, up 20.1% on the year before. Over five years, revenue changed +14.7% a year on average.
Hi! I read Concord Medical Services Holdings Ltdβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+20.1%
Yes. Sales grew 20.1% last year.
Does it make a profit?
β20.2%
No. It lost money last year.
Does profit turn into cash?
β56.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Concord Medical Services Holdings Ltd did it, and the next one. Share prices often move a lot on those days.
Next results
April 28, 2027
Wednesday Β· in 185 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Apr 29, 2026 | Period ended Dec 31, 2025 | Before the market opens | 20-F β |
| Apr 25, 2025 | Period ended Dec 31, 2024 | Before the market opens | 20-F β |
| Apr 19, 2024 | Period ended Dec 31, 2023 | Before the market opens | 20-F β |
| Apr 19, 2023 | Period ended Dec 31, 2022 | Before the market opens | 20-F β |
| Apr 29, 2022 | Period ended Dec 31, 2021 | After the market closes | 20-F β |
| Oct 15, 2021 | Period ended Dec 31, 2020 | After the market closes | 20-F β |
| Apr 30, 2020 | Period ended Dec 31, 2019 | After the market closes | 20-F β |
| Apr 30, 2019 | Period ended Dec 31, 2018 | After the market closes | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Concord Medical Services Holdings Ltd had $64.1M of revenue in fiscal 2025, up 20.1% on the year before. Over five years, revenue changed +14.7% a year on average. Its operating margin was β56.8%, up 81.8Β pts: of every 100 in sales, about β57 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Concord Medical Services Holdings Ltd lost $12.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$35.9M in fiscal 2025, β56.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Concord Medical Services Holdings Ltd owes $450M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Concord Medical Services Holdings Ltd can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.8M | $22.9M | $8.2M | $48.1M | $42.5M |
| Debt incl. finance leases | $390M | $433M | $427M | $511M | $492M |
| Interest coverage | β6.2x | β4.4x | β2.8x | β2.8x | β1.7x |
| Current ratio | 0.7x | 0.7x | 0.3x | 0.5x | 0.5x |
| Quick ratio | 0.7x | 0.6x | 0.3x | 0.4x | 0.5x |
| Total assets | $981M | $870M | $852M | $922M | $935M |
| Total liabilities | $549M | $578M | $606M | $700M | $671M |
| Shareholders' equity | β$216M | β$270M | β$299M | β$312M | β$300M |
| Net debt (β = net cash) | $365M | $410M | $419M | $462M | $450M |
KIRA Β· Its return on capital was β19.2%: every 100 invested in the business earned about β19 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Concord Medical Services Holdings Ltd passes 6 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 4 / 9 | 2 / 9 | 4 / 9 | 3 / 9 | 3 / 9 | 5 / 9 | 3 / 9 | 6 / 9 |
| Accruals ratio | β5.9% | β9.2% | β4.9% | β2.5% | β1.6% | 1.5% | β4.4% | β0.3% | 1.4% | 1.6% |
| Altman Z'' | 0.14 | β0.82 | β0.62 | β2.62 | β1.91 | β2.85 | β3.53 | β4.67 | β4.24 | β3.97 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $68.5M | $49.0M | $28.8M | $28.7M | $32.3M | $75.3M | $70.1M | $75.9M | $53.4M | $64.1M |
| Gross profit | $25.4M | $14.5M | $3.0M | β$2.3M | $1.9M | β$8.8M | β$22.6M | β$10.8M | β$11.0M | $3.6M |
| Operating income | β$25.4M | β$31.3M | β$45.2M | β$63.3M | β$45.8M | β$71.1M | β$78.0M | β$65.4M | β$73.9M | β$36.4M |
| Interest expense | $13.4M | $13.3M | $7.0M | $4.2M | $11.8M | $11.4M | $17.9M | $23.4M | $26.8M | $21.2M |
| Pretax income | $30.8M | $37.6M | $34.0M | $56.6M | $64.0M | $82.1M | β$125M | β$78.4M | β$93.0M | β$51.9M |
| Income tax | $9.1M | $4.7M | $5.1M | β$5.6M | β$5.5M | β$1.0M | β$10.5M | β$3.5M | β$2.4M | $0.8M |
| Net income | β$39.4M | β$42.1M | β$35.5M | β$44.4M | β$44.9M | β$42.1M | β$72.7M | β$42.0M | β$42.8M | β$12.9M |
| Net income to common | β$39.4M | β$42.1M | β$54.3M | β$80.0M | β$97.1M | β$127M | β$72.7M | β$42.0M | β$42.8M | β$12.9M |
| Diluted EPS | β$9.03 | β$9.72 | β$12.51 | β$18.41 | β$22.21 | β$29.12 | β$16.67 | β$9.62 | β$9.80 | β$2.96 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$11.8M | $4.0M | β$5.8M | β$28.3M | β$33.3M | β$55.7M | β$32.2M | β$39.0M | β$55.3M | β$28.1M |
| Capital expenditure | $11.9M | $13.5M | $25.0M | $33.7M | $24.3M | $43.3M | $33.1M | $16.0M | $21.0M | $7.8M |
| Free cash flow | β$23.6M | β$9.5M | β$30.9M | β$61.9M | β$57.6M | β$99.0M | β$65.3M | β$55.0M | β$76.2M | β$35.9M |
| Depreciation and amortization | $17.6M | $12.3M | $6.2M | $6.4M | $8.0M | $10.0M | $13.2M | $11.6M | $11.8M | $14.4M |
| Stock-based compensation | $1.3M | $1.7M | $1.7M | $3.0M | $3.0M | $2.3M | β$0.9M | $0.0M | β | β |
| Acquisitions | β$3.9M | $0.0M | $79.9M | $60.9M | $1.2M | β$0.2M | $0.0M | $0.0M | β | β |
| Share buybacks | $4.6M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Dividends paid | $43.0M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Dividends and buybacks | $47.6M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $27.3M | $15.1M | $66.1M | $10.7M | $51.1M | $24.8M | $22.9M | $8.2M | $48.1M | $42.5M |
| Total debt | $124M | $117M | $136M | $233M | $324M | $390M | $433M | $427M | $511M | $492M |
| Loans, net | β | β | $22.0M | $10.1M | $10.3M | $26.6M | $42.6M | β | β | β |
| Current assets | $172M | $171M | $179M | $40.6M | $103M | $92.0M | $110M | $86.9M | $135M | $135M |
| Current liabilities | $137M | $170M | $127M | $90.1M | $78.3M | $127M | $163M | $275M | $291M | $279M |
| Inventory | $0.9M | $1.0M | $0.5M | $0.6M | $3.3M | $6.0M | $12.3M | $5.7M | $4.6M | $6.6M |
| Property and equipment, net | $112M | $122M | $177M | $273M | $391M | $495M | $472M | $499M | $507M | $532M |
| Goodwill | β | β | $24.0M | $30.2M | $32.7M | $91.6M | $83.4M | $81.0M | $78.4M | $81.7M |
| Intangible assets | $2.5M | $1.2M | $66.4M | $76.5M | $80.0M | $104M | $51.3M | $45.5M | $40.0M | $36.6M |
| Total assets | $465M | $533M | $667M | $617M | $816M | $981M | $870M | $852M | $922M | $935M |
| Total liabilities | $288M | $377M | $336M | $346M | $449M | $549M | $578M | $606M | $700M | $671M |
| Shareholders' equity | $168M | $144M | $63.6M | β$17.6M | β$101M | β$216M | β$270M | β$299M | β$312M | β$300M |
| Margins | ||||||||||
| Gross margin | 37.0% | 29.6% | 10.4% | β8.0% | 5.9% | β11.7% | β32.3% | β14.3% | β20.6% | 5.6% |
| Operating margin | β37.1% | β64.0% | β156.8% | β220.5% | β141.7% | β94.4% | β111.2% | β86.2% | β138.6% | β56.8% |
| EBITDA margin | β11.3% | β38.9% | β135.4% | β198.1% | β117.0% | β81.1% | β92.4% | β70.9% | β116.5% | β34.3% |
| Net margin | β57.5% | β85.9% | β123.0% | β154.8% | β139.0% | β55.9% | β103.7% | β55.4% | β80.3% | β20.2% |
| FCF margin | β34.5% | β19.5% | β107.0% | β215.8% | β178.4% | β131.4% | β93.1% | β72.5% | β142.9% | β56.1% |
| Returns | ||||||||||
| Return on capital | β6.8% | β11.2% | β28.7% | β31.0% | β26.7% | β47.5% | β44.2% | β42.9% | β38.9% | β19.2% |
| Return on capital employed | β7.7% | β8.7% | β8.4% | β12.0% | β6.2% | β8.3% | β11.0% | β11.3% | β11.7% | β5.5% |
| Return on equity | β23.5% | β27.0% | β34.3% | β193.3% | β | β | β | β | β | β |
| Return on assets | β8.5% | β8.4% | β5.9% | β6.9% | β6.3% | β4.7% | β7.9% | β4.9% | β4.8% | β1.4% |
| Return on tangible equity | β23.8% | β29.6% | β | β | β | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β28.5% | β41.1% | β0.5% | 12.6% | 133.0% | β6.9% | 8.2% | β29.7% | 20.1% |
| Share count change | β | β0.4% | 0.0% | 0.1% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Financial health | ||||||||||
| Debt / equity | 0.7x | 0.8x | 2.1x | β | β | β | β | β | β | β |
| Interest coverage | β1.9x | β2.4x | β6.5x | β15.2x | β3.9x | β6.2x | β4.4x | β2.8x | β2.8x | β1.7x |
| Current ratio | 1.3x | 1.0x | 1.4x | 0.5x | 1.3x | 0.7x | 0.7x | 0.3x | 0.5x | 0.5x |
| Quick ratio | 1.3x | 1.0x | 1.4x | 0.4x | 1.3x | 0.7x | 0.6x | 0.3x | 0.4x | 0.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 17.3% | 27.6% | 86.7% | 117.3% | 75.3% | 57.4% | 47.2% | 21.0% | 39.3% | 12.2% |
| Stock comp / revenue | 1.8% | 3.5% | 5.8% | 10.4% | 9.2% | 3.0% | β1.3% | 0.0% | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 4.0 | 2.0 | 4.0 | 3.0 | 3.0 | 5.0 | 3.0 | 6.0 |
| Altman Z'' | 0.1 | β0.8 | β0.6 | β2.6 | β1.9 | β2.8 | β3.5 | β4.7 | β4.2 | β4.0 |
| Accruals ratio | β5.9% | β9.2% | β4.9% | β2.5% | β1.6% | 1.5% | β4.4% | β0.3% | 1.4% | 1.6% |
Source: SEC EDGAR XBRL filings (CIK 0001472072). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CNY under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 30 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.
